Setup, so nobody has to ask: retatrutide · fourteen days.
I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.
My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.
Is the standard explanation correct, and if so, what is the evidence for it?
Moving the day by 14 stretches one interval from 7 days to 21 — one interval, and then it is over. At a seven-day half-life the trough at the end of a normal week sits at 50 per cent of the preceding peak. At the end of a 21-day week it sits at 0.5^(21÷7) = 12.5 per cent: a fall of 37.5 percentage points, once, after which every interval is 7 days again. That is the entire pharmacokinetic content of the change. Whether 37.5 points of trough is worth anything is a question about your own tolerability curve rather than about the molecule. A move of 14 days is longer than the interval itself, which makes it not a shift at all but a missed dose followed by a new schedule — and it should be reasoned about as one. Timing changes are made under supervision; nothing here is medical advice.
To be exact about it, changing the regular dosing day is possible and should be done by moving forward, not by squeezing two doses together.
One missed dose is not a reason to change the schedule or the dose. Two or more is a reason to consider where you are restarting from.
| Agent | Start | Step interval | Maintenance range | Max studied |
|---|---|---|---|---|
| Semaglutide (weight management) | 0.25 mg/wk | 4 weeks | 1.7–2.4 mg/wk | 2.4 mg/wk |
| Semaglutide (T2DM) | 0.25 mg/wk | 4 weeks | 0.5–2.0 mg/wk | 2.0 mg/wk |
| Tirzepatide | 2.5 mg/wk | 4 weeks | 5–15 mg/wk | 15 mg/wk |
| Liraglutide (weight management) | 0.6 mg/day | 1 week | 3.0 mg/day | 3.0 mg/day |
| Oral semaglutide | 3 mg/day | 4 weeks | 7–14 mg/day | 50 mg/day (trial) |
Structure is identical across the class: small start, four-week steps, a defined maintenance range, a defined ceiling.
With a one-week half-life dosed weekly, missing one dose means exposure falls by about half over the following week — the same trough you would reach if you simply extended the interval. That is well within the range the agent operates in.
Loss of tolerance during a treatment gap is documented and is the basis for re-titration after an interruption.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Never double up. Peak exposure is what drives the symptoms.
edited 23 Sept 2024 by bounty_hunter_q — tightened the wording; no substantive change
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemAnswering this needs the agent, since the answer for a thirteen-hour half-life and a one-week half-life are entirely different.
The published guidance for the weekly agents is broadly: if the missed dose is remembered within about five days, take it and continue on the usual day; if more than five days have passed, skip it and take the next scheduled dose.
To change your regular dosing day, move the next dose later rather than earlier, keeping at least three days between doses for a weekly agent. Moving earlier compresses the interval and raises exposure.
Half-lives across the class span roughly thirteen hours to one week, which is why the answer is agent-specific.
Repeated missed doses are a different problem from an occasional one and should be treated as such.
To move your dosing day, move it later and keep three days between doses.
Start with the interval since the missed dose, because that single number determines the answer.
If more than two consecutive weekly doses are missed, tolerance to the gastrointestinal effects begins to fade and re-titration from a lower step becomes the sensible approach.
It helps to be literal here: for a daily agent with a thirteen-hour half-life, a missed dose is a much larger proportional loss. The usual approach is to skip it and take the next scheduled one rather than doubling.
Peak exposure rather than average exposure drives gastrointestinal tolerability, which is the reason doubling up is advised against.
The caveat is that anyone on other glucose-lowering medication has an interaction question here that needs a prescriber.
Two or more missed weekly doses means considering a lower restarting step.
Never double up to catch up. The exposure spike is real and the tolerability cost is immediate.
Never take two doses close together to compensate. The peak exposure is roughly doubled, and gastrointestinal tolerability tracks peak exposure closely.
Published missed-dose guidance for the weekly agents in this class specifies a window of about five days, derived directly from the half-life.
Set a recurring reminder attached to something you already do weekly.
Answer first: it depends on the half-life and on how long ago the dose was due, and for a weekly agent the tolerance is much wider than people fear.
Set a recurring reminder tied to something you already do weekly. The commonest cause of a missed dose is not forgetting the drug but losing track of the day.
The STEP programme escalated semaglutide over sixteen weeks in four-week steps to 2.4 mg weekly, and the trial-product estimand versus treatment-policy estimand distinction accounts for most of the difference between the figures quoted from those papers.
A published missed-dose window applies to a licensed product with a known content, which unverified material is not.
Within about five days for a weekly agent, take it. Beyond that, skip and resume.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.